News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
PCI Fellows Enjoy First In-Person Meeting of the Year
On September 19, the PCI Fellows got together for their first in-person meeting since the cohort began in April.
Team of Leading Scientists unite to launch Capstan Therapeutics
Penn spinout Capstan Therapeutics unites decades of combined experience in groundbreaking CAR therapies with the latest advances in mRNA delivery technology to find new cures for cancer and other dise
Innervace Secures Up to $40 Million to Advance Novel Regenerative Medicine Platform for Neurological Disorders
Innervace, a regenerative medicine startup cofounded by Penn Medicine’s Kacy Cullen, PhD, and Douglas Smith, PhD raised up to $40 million in Series A financing.
iECURE Gets Early FDA Designation
The company was awarded FDA orphan drug designation for its experimental therapy, GTP-506, on the heels of the drug receiving rare pediatric disease designation.
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
The combined company, which is expected to operate under the name Carisma Therapeutics Inc., will focus on advancing Carisma’s proprietary cell therapy platform.
Five Philadelphia Organizations Are Partnering for a New Biotech Technician Training Program Starting this Fall
Five organizations will partner for a paid workforce development training program called Biomedical Technician Training Program: Aseptic Manufacturing.
Penn Engineering Commercialization Speaker Series
This fall, the Penn Center for Innovation and Penn Engineering present three monthly sessions with expert speakers, who will discuss funding, pitching, and open source software for commercialization.
Penn spinout Capstan Therapeutics Launches with Goal of Incorporating mRNA into CAR-T Cell Therapy
This new approach to CAR-T therapy will involve mRNA therapy that directs cells in the body to make proteins to prevent or fight disease.
Tech of the Month: AI-Powered Optical Tool for Fluorescence-Guided Oncological Surgery
This tool provides immediate and accurate tumor identification without the frozen section staining process normally required, saving over 30 minutes and thousands of dollars per tumor per operation.
Jim Wilson Speaks on What’s Next for Cell and Gene Therapy in Philadelphia
On September 8, Jim Wilson, director of Penn Medicine's gene therapy program and director of Penn's orphan disease center. sat down with health care reporter John George for a wide-ranging discussion.